The Friendswood-based company reported a 32% increase in total test reports for its primary revenue drivers, DecisionDx-Melanoma and TissueCypher, compared to the same period last year. Despite a net loss of $2.1 million for the quarter—largely attributed to $11.6 million in non-cash stock-based compensation—the firm maintains a strong liquidity position, holding $266.8 million in cash and marketable securities as of June 30, 2026.
Castle Biosciences Raises 2026 Outlook After Revenue Growth
With second-quarter revenue climbing to $103.5 million, Castle Biosciences is lifting its full-year financial forecast to a range of $365 million to $375 million. The diagnostics company credits the upward revision to robust demand for its core testing products, specifically in oncology and gastroenterology.
Derek Maetzold, president and chief executive officer of Castle Biosciences, stated that the growth reflects the clinical value of the firm's diagnostic portfolio. Looking ahead, the company expects to reach positive Adjusted EBITDA for the remainder of the year. Beyond financial performance, Castle continues to advance its clinical pipeline, recently initiating the DETECT-AD study to explore early intervention strategies for atopic dermatitis patients.
Comments (0)
No comments yet. Be the first!